The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective

Elevation of the proinflammatory cytokine Interleukin-1 (IL-1) is an integral part of the local tissue reaction to central nervous system (CNS) insult. The discovery of increased IL-1 levels in patients following acute injury and in chronic neurodegenerative disease laid the foundation for two decades of research that has provided important details regarding IL-1's biology and function in the CNS. IL-1 elevation is now recognized as a critical component of the brain's patterned response to insults, termed neuroinflammation, and of leukocyte recruitment to the CNS. These processes are believed to underlie IL-1's function in the setting of acute brain injury, where it has been ascribed potential roles in repair as well as in exacerbation of damage. Explorations of IL-1's role in chronic neurodegenerative disease have mainly focused on Alzheimer disease (AD), where indirect evidence has implicated it in disease pathogenesis. However, recent observations in animal models challenge earlier assumptions that IL-1 elevation and resulting neuroinflammatory processes play a purely detrimental role in AD, and prompt a need for new characterizations of IL-1 function. Potentially adaptive functions of IL-1 elevation in AD warrant further mechanistic studies, and provide evidence that enhancement of these effects may help to alleviate the pathologic burden of disease.

[1]  Carl Nathan,et al.  Neutrophils and immunity: challenges and opportunities , 2006, Nature Reviews Immunology.

[2]  S. Barger,et al.  Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway , 2003, The Journal of Neuroscience.

[3]  S. Allan,et al.  Interleukin‐1 in the Brain , 2003 .

[4]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[5]  S. Rivest,et al.  Role of IL-1 and TNF in the brain: Twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system , 2007, Brain, Behavior, and Immunity.

[6]  C. Ferrari,et al.  Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.

[7]  Michal Schwartz,et al.  Selective ablation of bone marrow‐derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model , 2007, The European journal of neuroscience.

[8]  L. Grimaldi,et al.  The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk , 2000, Experimental Gerontology.

[9]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[10]  S. Paul,et al.  Neuroinflammation‐induced acceleration of amyloid deposition in the APPV717F transgenic mouse , 2001, The European journal of neuroscience.

[11]  S. Paul,et al.  Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. , 2000, Journal of neurochemistry.

[12]  C. Ferrari,et al.  Differential effects of interleukin-1β on neurotoxicity, cytokine induction and glial reaction in specific brain regions , 2005, Journal of Neuroimmunology.

[13]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[14]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[15]  D. Jurič,et al.  Interleukin-1 beta, but not IL-1 alpha, mediates nerve growth factor secretion from rat astrocytes via type I IL-1 receptor. , 2001, International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience.

[16]  C. Dinarello,et al.  Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. , 1986, Science.

[17]  M. O’Banion,et al.  Chronic Interleukin-1β Expression in Mouse Brain Leads to Leukocyte Infiltration and Neutrophil-Independent Blood–Brain Barrier Permeability without Overt Neurodegeneration , 2007, The Journal of Neuroscience.

[18]  P. Feng,et al.  IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.

[19]  G. Higgins,et al.  Induction of interleukin-1β mRNA in adult rat brain , 1991 .

[20]  C. Lemere,et al.  Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice , 2006, Glia.

[21]  D. Wilcock,et al.  Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration , 2004, Neurobiology of Disease.

[22]  M. O’Banion,et al.  Intraparenchymal administration of interleukin-1β induces cyclooxygenase-2-mediated expression of membrane- and cytosolic-associated prostaglandin E synthases in mouse brain , 2004, Journal of Neuroimmunology.

[23]  T. Standiford,et al.  Chemokine-Dependent Neutrophil Recruitment in a Murine Model of Legionella Pneumonia: Potential Role of Neutrophils as Immunoregulatory Cells , 2001, Infection and Immunity.

[24]  D. Chaplin,et al.  Interleukin-1β Promotes Repair of the CNS , 2001, The Journal of Neuroscience.

[25]  D. Wilcock,et al.  Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.

[26]  P. Carvey,et al.  Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. , 2005, Journal of neural transmission.

[27]  N. Rothwell,et al.  Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. , 2008, British journal of clinical pharmacology.

[28]  W. Wood,et al.  Chemokine binding and activities mediated by the mouse IL-8 receptor. , 1995, Journal of immunology.

[29]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[30]  T. Montine,et al.  Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease , 2003, Journal of Neuroimmunology.

[31]  A. Betz,et al.  Expression of intercellular adhesion molecule 1 (ICAM-1) is reduced in permanent focal cerebral ischemic mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. , 1999, Brain research. Molecular brain research.

[32]  Michael T. Heneka,et al.  Inflammatory processes in Alzheimer's disease , 2007, Journal of Neuroimmunology.

[33]  J. Garcìa,et al.  Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. , 1995, The American journal of pathology.

[34]  E. Wada,et al.  In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  Damijana M. Jurič,et al.  Interleukin-1β, but not IL-1α, mediates nerve growth factor secretion from rat astrocytes via type I IL-1 receptor , 2001, International Journal of Developmental Neuroscience.

[36]  S. Hauser,et al.  Cytokine accumulations in CSF of multiple sclerosis patients , 1990, Neurology.

[37]  D. Chaplin,et al.  Interleukin-1beta promotes repair of the CNS. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  R. Mrak,et al.  Neuritic plaque evolution in Alzheimer’s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms , 1997, Acta Neuropathologica.

[39]  A. Coogan,et al.  Actions of the Pro‐Inflammatory Cytokine Il‐1[beta] on Central Synaptic Transmission , 1999, Experimental physiology.

[40]  P. Mcgeer,et al.  Polymorphisms in inflammatory genes and the risk of Alzheimer disease. , 2001, Archives of neurology.

[41]  N. Rothwell,et al.  Neuroprotective actions of endogenous interleukin‐1 receptor antagonist (IL‐1ra) are mediated by glia , 2006, Glia.

[42]  R. Green,et al.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.

[43]  R. Mrak,et al.  Increased Neuronal β‐Amyloid Precursor Protein Expression in Human Temporal Lobe Epilepsy: Association with Interleukin‐1α Immunoreactivity , 1994 .

[44]  L. V. Van Eldik,et al.  Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid , 2005, Journal of Neuroinflammation.

[45]  G. Cole,et al.  The microglial phagocytic role with specific plaque types in the Alzheimer disease brain , 2004, Neurobiology of Aging.

[46]  G. Almazan,et al.  Interleukin-1 Regulates Proliferation and Differentiation of Oligodendrocyte Progenitor Cells , 2002, Molecular and Cellular Neuroscience.

[47]  S. Barger,et al.  Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E , 1997, Nature.

[48]  Julia W. Chang,et al.  Interleukin‐1β Induces Prostaglandin G/H Synthase‐2 (Cyclooxygenase‐2) in Primary Murine Astrocyte Cultures , 1996, Journal of neurochemistry.

[49]  A. Dunn Cytokine Activation of the HPA Axis , 2000, Annals of the New York Academy of Sciences.

[50]  R. Mrak,et al.  Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. , 1994, Journal of neurochemistry.

[51]  S. Levison,et al.  Interleukin‐1: A master regulator of neuroinflammation , 2004, Journal of neuroscience research.

[52]  D. Morgan,et al.  Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice , 2004, Experimental Neurology.

[53]  R. Mrak,et al.  Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.

[54]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Carvey,et al.  Intra-parenchymal injection of tumor necrosis factor-α and interleukin 1-β produces dopamine neuron loss in the rat , 2005, Journal of Neural Transmission.

[56]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[57]  M. Wolfe,et al.  Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. , 2004, The Journal of biological chemistry.

[58]  R. Bartus,et al.  The Role of Leukocytes Following Cerebral Ischemia: Pathogenic Variable or Bystander Reaction to Emerging Infarct? , 2002, Experimental Neurology.

[59]  P. Mcgeer,et al.  Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR , 1987, Neuroscience Letters.

[60]  J. Tichelaar,et al.  Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. , 2005, American journal of respiratory cell and molecular biology.

[61]  C. Ferrari,et al.  Learning modulation by endogenous hippocampal IL‐1: Blockade of endogenous IL‐1 facilitates memory formation , 2004, Hippocampus.

[62]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[63]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[64]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .

[65]  S. DeKosky,et al.  The Type 1 Interleukin-1 Receptor Is Essential for the Efficient Activation of Microglia and the Induction of Multiple Proinflammatory Mediators in Response to Brain Injury , 2002, The Journal of Neuroscience.

[66]  S. Shioda,et al.  Lipopolysaccharide‐induced microglial activation induces learning and memory deficits without neuronal cell deathin rats , 2006, Journal of neuroscience research.

[67]  D. Borchelt,et al.  Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice , 2003, Neurobiology of Disease.

[68]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[69]  R. Ransohoff,et al.  Three or more routes for leukocyte migration into the central nervous system , 2003, Nature Reviews Immunology.

[70]  F. Dhabhar,et al.  Neurotoxic effects of polymorphonuclear granulocytes on hippocampal primary cultures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  V. Perry,et al.  Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. , 1997, Brain : a journal of neurology.

[72]  L. Mucke,et al.  TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. , 2001, Nature medicine.

[73]  Y. L. Dubreuil,et al.  Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  H. Soininen,et al.  Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[75]  K. Mohler,et al.  Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. , 1992, Journal of immunology.

[76]  J. W. Rudy,et al.  The immune system and memory consolidation: a role for the cytokine IL-1β , 2001, Neuroscience & Biobehavioral Reviews.

[77]  C. Pert,et al.  Visualization and characterization of interleukin 1 receptors in brain. , 1987, Journal of immunology.

[78]  V. Perry,et al.  Differential regulation of type I and type II interleukin‐1 receptors in focal brain inflammation , 2005, The European journal of neuroscience.

[79]  N. Rothwell,et al.  Gene regulation by IL‐1β independent of IL‐1R1 in the mouse brain , 2006, Glia.

[80]  S. Karlsson,et al.  Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice , 2005, Neurobiology of Disease.

[81]  E. Connolly,et al.  Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. , 1996, The Journal of clinical investigation.

[82]  N. Rothwell,et al.  Interleukin-1 Influences Ischemic Brain Damage in the Mouse Independently of the Interleukin-1 Type I Receptor , 2002, The Journal of Neuroscience.

[83]  W. Benzing,et al.  Evidence for glial-mediated inflammation in aged APPSW transgenic mice , 1999, Neurobiology of Aging.

[84]  Detlef Balschun,et al.  A neuromodulatory role of interleukin-1β in the hippocampus , 1998 .

[85]  I. Goshen,et al.  Impaired interleukin‐1 signaling is associated with deficits in hippocampal memory processes and neural plasticity , 2003, Hippocampus.

[86]  D. Graham,et al.  Microglial interleukin-lα expression in human head injury: Correlations with neuronal and neuritic β-amyloid precursor protein expression , 1994, Neuroscience Letters.

[87]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[88]  B. Winblad,et al.  Immunohistochemical localization of interleukin-1β, interleukin-1 receptor antagonist and interleukin-1β converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid , 1999, Neuroscience.

[89]  N. Rothwell Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential , 2003, Brain, Behavior, and Immunity.

[90]  D. Coppola,et al.  Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.

[91]  N. Rothwell,et al.  Interleukin‐1‐induced neurotoxicity is mediated by glia and requires caspase activation and free radical release , 2006, Journal of neurochemistry.

[92]  F. Pitossi,et al.  A neuromodulatory role of interleukin-1beta in the hippocampus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[93]  P. Liberski,et al.  Molecular analysis of prion protein (PrP) and glial fibrillary acidic protein (GFAP) transcripts in experimental Creutzfeldt-Jakob disease in mice. , 1997, Acta neurobiologiae experimentalis.

[94]  Sunhee C. Lee,et al.  Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis , 2001, Journal of Neuroimmunology.

[95]  M. Herkenham,et al.  Intracerebroventricular but not intravenous interleukin-1β induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation , 2002, Neuroscience.

[96]  R. Skinner,et al.  In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis , 1996, Neurobiology of Aging.

[97]  J. W. Rudy,et al.  The immune system and memory consolidation: a role for the cytokine IL-1beta. , 2001, Neuroscience and biobehavioral reviews.

[98]  J. Julien,et al.  Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease , 2006, Neuron.

[99]  P. Morrissey,et al.  Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. , 1997, Journal of immunology.

[100]  M. Wong,et al.  Endogenous interleukin-1 receptor antagonist is neuroprotective. , 1997, Biochemical and biophysical research communications.

[101]  Soumaya Bennouna,et al.  CXCR2 Deficiency Confers Impaired Neutrophil Recruitment and Increased Susceptibility During Toxoplasma gondii Infection1 , 2001, The Journal of Immunology.

[102]  Brian J. Bacskai,et al.  Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.

[103]  T. Montine,et al.  Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[104]  W. Griffin,et al.  Interleukin-1 Promotes Expression and Phosphorylation of Neurofilament and tau Proteins in Vivo , 2000, Experimental Neurology.

[105]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[106]  M. Wolfe,et al.  Tumor Necrosis Factor-α, Interleukin-1β, and Interferon-γ Stimulate γ-Secretase-mediated Cleavage of Amyloid Precursor Protein through a JNK-dependent MAPK Pathway* , 2004, Journal of Biological Chemistry.

[107]  N. Rothwell,et al.  Interleukin-1 Receptor Antagonist Penetrates Human Brain at Experimentally Therapeutic Concentrations , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[108]  S. McColl,et al.  Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-alpha. , 1997, Journal of immunology.

[109]  L. Mucke,et al.  TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.

[110]  F. LaFerla,et al.  Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice , 2005, Journal of Neuroinflammation.

[111]  D. Graham,et al.  Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. , 1994, Neuroscience letters.

[112]  M. O’Banion,et al.  Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. , 2007, The Journal of clinical investigation.

[113]  D. Wallach,et al.  MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1 , 1997, Nature.

[114]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[115]  H. Besedovsky,et al.  Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. , 1987, Science.

[116]  S. Barger,et al.  Journal of Neuroinflammation Interleukin-1 Mediates Alzheimer and Lewy Body Pathologies , 2022 .

[117]  B. Melchior,et al.  CNS immune privilege: hiding in plain sight , 2006, Immunological reviews.

[118]  V. Perry,et al.  Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. , 2004, The American journal of pathology.

[119]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[120]  N. Rothwell,et al.  Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat , 1995, Brain Research.

[121]  B. Trapp,et al.  Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. , 1996, The Journal of clinical investigation.

[122]  P. Aisen,et al.  Randomized pilot study of nimesulide treatment in Alzheimer’s disease , 2002, Neurology.

[123]  N. Rothwell,et al.  Interleukin-1 and neuronal injury , 2005, Nature Reviews Immunology.

[124]  P. Cras,et al.  The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease , 2002, Neurobiology of Aging.

[125]  R. P. Stroemer,et al.  Exacerbation of Ischemic Brain Damage by Localized Striatal Injection of Interleukin-1β in the Rat , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[126]  R. Mrak,et al.  Trisomy 21 and the Brain , 2004, Journal of neuropathology and experimental neurology.

[127]  T. Standiford,et al.  CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. , 1999, Journal of immunology.

[128]  M. Morganti-Kossmann,et al.  Inflammatory response in acute traumatic brain injury: a double-edged sword , 2002, Current opinion in critical care.

[129]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[130]  S. Styren,et al.  Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease , 1988, Neurobiology of Aging.

[131]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[132]  C. Gray,et al.  Regulation of β-amyloid precursor protein isoform mRNAs by transforming growth factor-β1 and interleukin-1β in astrocytes , 1993 .

[133]  N. Delanty,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1998, Neurology.

[134]  N. Rothwell,et al.  A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[135]  S. Levison,et al.  Astrogliosis is delayed in type 1 interleukin-1 receptor-null mice following a penetrating brain injury , 2006, Journal of Neuroinflammation.

[136]  J. Rogers,et al.  Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. , 2006, Journal of Alzheimer's disease : JAD.

[137]  B. Davidson,et al.  Attenuation of Ischemic Inflammatory Response in Mouse Brain Using an Adenoviral Vector to Induce Overexpression of Interleukin-1 Receptor Antagonist , 1998, Journal of Cerebral Blood Flow and Metabolism.

[138]  D. Wilcock,et al.  Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. , 2004, Neurobiology of disease.

[139]  T. Baram,et al.  Interleukin‐1β contributes to the generation of experimental febrile seizures , 2005, Annals of neurology.

[140]  S. Rivest,et al.  Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease , 2006, Molecular Psychiatry.

[141]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[142]  R. Mrak,et al.  Glial‐Neuronal Interactions in Alzheimer Disease: Progressive Association of IL‐1α+ Microglia and S100β+ Astrocytes with Neurofibrillary Tangle Stages , 1997, Journal of neuropathology and experimental neurology.

[143]  W. Hickey,et al.  CXC Chemokine Receptor-2 Ligands Are Required for Neutrophil-Mediated Host Defense in Experimental Brain Abscesses1 , 2001, The Journal of Immunology.

[144]  M. Bukrinsky,et al.  Cytokine‐stimulated astrocytes damage human neurons via a nitric oxide mechanism , 1996, Glia.

[145]  S. Allan,et al.  Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. , 2003, Annals of the New York Academy of Sciences.

[146]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[147]  R. Mrak,et al.  Glial Cytokines as Neuropathogenic Factors in HIV Infection: Pathogenic Similarities to Alzheimer's Disease , 1994, Journal of neuropathology and experimental neurology.

[148]  N. Rothwell,et al.  CNS injury: the role of the cytokine IL-1. , 2004, Veterinary journal.

[149]  T. Golde,et al.  Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Aβ immunotherapy , 2006, Journal of Neuroinflammation.

[150]  V. Perry,et al.  OVERRIDING THE BRAIN'S INTRINSIC RESISTANCE TO LEUKOCYTE RECRUITMENT WITH INTRAPARENCHYMAL INJECTIONS OF RECOMBINANT CHEMOKINES , 1996, Neuroscience.

[151]  E. Scarpini,et al.  Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with β-amyloid[25–35] , 1999, Journal of Neuroimmunology.

[152]  T. Nagatsu,et al.  Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.

[153]  V. Perry,et al.  CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood–brain barrier breakdown , 1998, Current Biology.

[154]  Šimon Scharf,et al.  A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.

[155]  C. Lemere,et al.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.

[156]  W. Griffin,et al.  The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. , 1997, Journal of neurovirology.

[157]  W. Griffin,et al.  Overexpression of the Neuritotrophic Cytokine S100β Precedes the Appearance of Neuritic β‐Amyloid Plaques in APPV717F Mice , 2000 .

[158]  S. Rogers,et al.  Inflammatory Cytokines IL-1α, IL-1β, IL-6, and TNF-α Impart Neuroprotection to an Excitotoxin Through Distinct Pathways , 1999, The Journal of Immunology.

[159]  N. Quan,et al.  IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system , 2005, Brain, Behavior, and Immunity.

[160]  N. Rothwell,et al.  Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[161]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[162]  W. Griffin,et al.  Distribution of interleukin‐1‐immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer’s disease , 1998, Neuropathology and applied neurobiology.

[163]  S. Rogers,et al.  Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. , 1999, Journal of immunology.

[164]  C. Dijkstra,et al.  Demonstration of interleukin-1β in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level , 1993, Journal of Neuroimmunology.

[165]  W. Griffin,et al.  Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression , 1998, Brain pathology.

[166]  K. Smith,et al.  Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis , 1997, Journal of Neuroimmunology.

[167]  C. Cahill,et al.  Translation of the Alzheimer Amyloid Precursor Protein mRNA Is Up-regulated by Interleukin-1 through 5′-Untranslated Region Sequences* , 1999, The Journal of Biological Chemistry.